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1. Introduction
   Organic compound synthesis has been promoted by 
microwave assisted methods by which small molecules 
are built up into large polymers in a fraction of time when 
compared to thermal methods ensuring the acceptance 
of Microwave assisted irradiation reactions as a valuable 
tool for acceleration of a wide variety of organic molecules 
development[1-3]. The advent of microwave assisted 
technology in organic chemistry dates back to the mid 1980s 
and since the 1990s there has been a significant increase in 
the number of publications on Microwave Assisted Organic 
Reactions (MAOS) due to increased benefits associated 
with the process[4-6]. The promotion of microwave assisted 
reactions in organic chemistry has improved the speed, 
reduced cost, reduced energy spent making it a sustainable 
process and is widely heralded as “green chemistry” 
measures whose applications are promoted today to 
minimize the use of non renewable resources as well 
as polluting solvent, to reduce generation of secondary 
products which are often toxic and to reduce the emission of 
harmful gases[7-9]. Microwave assisted reactions in organic 
chemistry achieve the same by ensuring facilitation of 
faster reactions under bulk conditions as well as promoting 
reduction of reaction time[10].
   Pyrimidine derivatives comprise a diverse and interesting 
group of drugs are extremely important for their biological 
activities. Dihydropyrimidine and their derivatives have 
attracted increasing interest owing to their therapeutic and 
pharmaceutical properties, such as antiviral, antibacterial, 
antitubercular[11-13], antagonists of the human adenosine 
A2A receptor[14], cyclooxygenase-2 inhibitory activity[15-
16], tyrosine kinase inhibitors, antiamoebic activity[17-
18]and anticancer activities[19]. Recently, functionalized 
dihydropyrimidinones have been successfully used 
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as antihypertensive agents, calcium channel blockers, 
adrenergic and neuropeptide Y (NPY) antagonists[20]. In 
addition, some alkaloids containing the dihydropyrimidine 
core unit which also exhibit interesting biological properties 
have been isolated from marine sources. Most notably, 
among these are the batzelladine alkaloids, which were 
found to be potent HIV gp-120-CD4 inhibitors[21-22]. The 
original protocol for the synthesis of dihydropyrimidinones, 
reported by Biginelli in 1893, involves a one-pot reaction of 
benzaldehyde, ethyl acetoacetate and urea in ethanol under 
strongly acidic conditions[23]. However, this method suffers 
from drawbacks such as low yields (20%-40%) of the desired 
products, particularly in case of substituted aldehydes, 
and loss of acid sensitive functional groups during the 
reaction. This has led to multi-step synthetic strategies 
that produce somewhat better yields, but which lack the 
simplicity of the original one-pot Biginelli protocol[24]. 
The discovery during the 1930s that a dihydropyridine 
(dihydronicotinamide derivative, NADH), ‘‘hydrogen-
transferring coenzyme’’ consequently became important 
in biological system, has generated numerous studies on 
the biochemical properties of dihydropyridines and their 
bioisosteres dihydropyrimidines. The search for more 
suitable preparation of dihydropyrimidinones continues 
today. 
   The chemical structure of isoniazid provides a most 
valuable molecular template for the development of 
agents able to interact with a wide variety of biological 
activities. Tetrahydropyrimidines are structurally similar to 
dihydropyrimidines. The synthesis of isoniazid condensed 
with 1, 2, 3, 4-tetrahydropyrimidinones are not reported 
so for. Hence, it was thought worthwhile to synthesize 
new congeners by incorporating isoniazid with 1, 2, 3, 
4-tetrahydropyrimidinones moieties in a single molecular 
frame work and to evaluate their antimicrobial and 
antimycobacterial activity.
2. Materials and methods 
2.1. Experimental
   All chemicals were supplied by E. Merck (Germany) and 
S.D fine chemicals (India). Melting points were determined 
by open tube capillary method and are uncorrected. Purity of 
the compounds was checked on thin layer chromatography 
(TLC) plates (silica gel G) in the solvent system ethanol, 
chloroform, ethylacetate (6:3:1); the spots were located under 
iodine vapors or UV light. IR spectrums were obtained on 
a Perkin-Elmer 1720 FT-IR spectrometer (KBr Pellets). 
1
H-NMR spectra were recorded or a Bruker AC 300 MHz 
spectrometer using TMS as internal standard in DMSO/ 
CDCl3. Mass spectra were obtained using Shimadzu LCMS 
2010A under ESI ionization technique.
2.2. General procedure
2.2.1. Preparation of N’-acetoacetylisonicotinohydrazide (3)
   Isoniazid 1 (0.01 M) and ethyl acetoacetate 2 (0.01 M) were 
mixed and refluxed for approximately 7 h. The colorless 
liquid formed was then heated on a water bath to remove 
the alcohol formed during the reaction. After allowing the 
reaction mixture to cool, crude crystals were obtained. 
Purification was performed by stirring crude crystals 
with cold diethyl ether for approximately 15 min using a 
mechanical stirrer. Allowing it to stand for 15 min, followed 
by filtration, resulted in the third compound in a pure form 
of N’-acetoacetylisonicotinohydrazide 3.
2.2.2. Preparation of 1,2,3,4-tetrahydropyrimidines by 
microwave irradiation method(4a-n)
   The mixture of N’-acetoacetylisonicotinohydrazide (0.005 
M), urea/thiourea (0.007 5 M), and appropriate aldehyde 
(0.005 M) with catalytic amount of benzenesulphonic acid 
in 10 ml of ethanol was subjected to microwave irradiation 
(300 W) for 8 min at the interval of 10 s. The reactions were 
monitored through TLC using 25 percent ethyl acetate in pet 
ether as solvent system. After the reaction was complete, the 
reaction mixture was cooled in a refrigerator and filtered. 
The precipitate obtained was washed thoroughly with water 
to remove unreacted urea/thiourea and dried. The crude 
solid product was recrystallized with ethanol to give the pure 
compounds (4a-n).
2.3. Analytical data
2.3.1. N’-(3-oxobutanoyl) pyridine-4-carbohydrazide (3)
   Colourless  crystalline solid, M.P: 174-176 曟, Yield 
68%, IR (KBr, cm-1): 3 312 (N-H), 3 052 (Ht-ArC-H), 2 864 
(AliC-H), 1 732 (C=O, ketone), 1 652 (C=O, amide), 1 563 
(C=C), 1 348 (C-N), 1H-NMR (DMSO-d6) δ: 2.28 (s, 3H, CH3), 
3.36 (s, 2H, CH2), 7.32 (d, 2H, ArH), 9.38 (s, 1H, NH), 9.38 (s, 
1H, NH), MS (m/z): M+ calculated 221.07, found 221.24.
2.3.2. 6-methyl-2-oxo-4-(pyridin-4-yl)-N’-(pyridin-4-
ylcarbonyl)-1,2,3,4 tetrahydropyrimidine-5-carbohydrazide 
(4a)
   Pale-bluish colored solid, M.P: 236-238 曟, Yield 72%, IR 
(KBr, cm-1): 3 296 (N-H), 3 136(ArC-H), 2 942 (AliC-H), 1 675 
(C=O, amide), 1 556 (C=C), 1 210 (O-C),  1H-NMR (DMSO-d6)
毮: 2.05 (s, 3H, CH3), 5.42 (s, 1H, CH), 6.52-6.67(d, 2H, ArH), 
7.24-7.35 (m, 5H, ArH), 7.54 (d, 2H, ArH), 8.71 (s, 1H, NH), 
8.85 (s,1H, NH), 9.42 (s, 1H, NH), 9.86 (s, 1H, NH). MS (m/z): 
M+ calculated 352.12, found 351.92.
2.3.3. 6-methyl-4-(pyridin-4-yl)-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4 tetrahydropyrimidine-5-
carbohydrazide(4b)
   Pale-yellowish solid, M.P: 248-251 曟, Yield 70%, IR 
(KBr, cm-1): 3 264 (N-H), 3 178(ArC-H), 2 956 (AliC-H), 1 
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685 (C=O, amide), 1 574 (C=C), 1 872 (C=S), 1 169 (O-C), 1H-
NMR (DMSO-d6)毮: 2.07 (s, 3H, CH3), 5.53(s, 1H, CH), 6.57 
(d, 2H, ArH), 7.31-7.45 (m, 5H, ArH), 7.82 (d, 2H, ArH), 9.22 
(s, 1H, NH), 9.58 (s, 1H, NH), 9.85 (s, 1H, NH), MS (m/z): M+ 
calculated 353, found 353.75. MS (m/z): M+ calculated 368.10, 
found 368.40.
2.3.4. 6-methyl-4-(3-nitrophenyl)-2-oxo-N’-(pyridin-4-
ylcarbonyl)-1,2,3,4 tetrahydropyrimidine-5-carbohydrazide 
(4c)
   Light-greenish colored solid, M.P: 256-259 曟, Yield 78%, 
IR (KBr, cm-1): 3 314 (N-H), 3 210 (ArC-H), 2 936 (AliC-H), 1 
684 (C=O, amide), 1 568 (C=C), 1 324 (O-C), 1H-NMR (DMSO-
d6)毮: 2.05 (s, 3H, CH3), 5.62 (s, 1H, CH),6.53 (d, 2H, ArH), 
6.74-7.21 (m, 4H, ArH), 7.56 (d, 2H, ArH), 8.52 (s, 1H, NH), 
8.76 (s, 1H, NH), 9.54 (s, 1H, NH). MS (m/z): M+ calculated 
396.11, found 395.96.
2.3.5. 6-methyl-4-(3-nitrophenyl)-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4d)
   Dark-brownish solid, M.P: 278-280 曟, Yield 74%, IR 
(KBr, cm-1): 3 228 (N-H), 3 146(ArC-H), 2 930 (AliC-H), 1 672 
(C=O, amide), 1 584 (C=C), 1858 (C=S), 1 210(O-C), 1H-NMR 
(DMSO-d6)毮: 2.04 (s, 3H, CH3), 5.38 (s, 1H, CH), 6.59 (d, 2H, 
ArH), 6.84 (d, 2H, ArH), 7.32 (d, 2H, ArH), 7.64 (d, 2H, ArH), 
9.24 (s, 1H, NH), 9.46 (s, 1H, NH), 9.88(s, 1H, NH). MS (m/z): 
M+ calculated 412.09, found 413.26.
2.3.6. 4-(3-chlorophenyl)-6-methyl-2-oxo-N’-
(pyridin-4-ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4e)
   Light-ash-colored solid, M.P: 263-266 曟, Yield 81%, IR 
(KBr, cm-1): 3 322 (N-H), 3178 (ArC-H), 2 942 (AliC-H), 1 667 
(C=O amide), 1 568 (C=C), 1 276 (C-O), 1HNMR (DMSO-d6)毮
:2.01 (s, 3H, CH3), 5.61 (s, 1H, CH), 6.72 (d, 2H, ArH), 7.54 (m, 
3H, ArH), 7.78 (d, 2H, ArH), 8.75 (s, 1H, NH), 9.44 (s, 1H, NH), 
9.88 (s, 1H, NH). MS (m/z): MS (m/z): M+ calculated 385.09, 
found 386.12.
2.3.7. 4-(3-chlorophenyl)-6-methyl-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4f)
   Ash-colored solid, M.P: 284-287 曟, Yield 78%, IR (KBr, 
cm-1): 3 257 (N-H), 3 156(ArC-H), 2 966 (AliC-H), 1 648 
(C=O, amide), 1 588 (C=C), 1 846 (C=S), 1 177 (O-C), 1H-
NMR (DMSO-d6)毮: 2.07 (s, 3H,CH3), 5.58 (s, 1H, CH), 6.72 
(d, 2H, ArH), 6.89 (d, 2H, ArH),7.66-7.82 (m, 3H, ArH), 9.24 
(s, 1H, NH), 9.47 (s, 1H, NH), 10.01 (s, 1H, NH), MS (m/z): M+ 
calculated 401.07, found 400.94.
2.3.8. 4-(furan-2-yl)-6-methyl-2-oxo-N’-(pyridin-
4-ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4g)
   Light-yellowish solid, M.P: 242-245 曟, Yield 77%, IR (KBr, 
cm-1): 3 252 (N-H), 3 146(ArC-H), 2 954 (AliC-H), 1 664 (C=O, 
amide), 1 586 (C=C), 1 174 (O-C), 1H-NMR (DMSO-d6)毮: 
2.01 (s, 3H, CH3), 5.43 (s, 1H, CH), 6.54 (d, 2H, ArH), 7.39-7.63 
(m, 4H, ArH), 8.92 (s, 1H, NH), 9.44 (s, 1H, NH), 9.92 (s, 1H, 
NH). MS (m/z): M+ calculated 341.11, found 340.86.
2.3.9. 4-(furan-2-yl)-6-methyl-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4h)
   Light-greenish solid, M.P: 268-271 曟, Yield 75%, IR 
(KBr, cm-1): 3 246 (N-H), 3 164(ArC-H), 2 968 (AliC-H), 1 638 
(C=O, amide), 1 566 (C=C), 1 846 (C=S), 1 154 (O-C), 1H-NMR 
(DMSO-d6)毮: 2.08 (s, 3H, CH3), 5.73 (s, 1H, CH), 6.51 (d, 2H, 
ArH), 7.38-7.56 (m, 4H, ArH), 8.94 (s, 1H, NH), 9.28 (s, 1H, 
NH), 9.93 (s, 1H, NH). MS (m/z): M+ calculated 357.08, found 
356.93.
2.3.10. 4-(2-chlorophenyl)-6-methyl-2-oxo-N’-
(pyridin-4-ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4i)
   Light-bluish solid, M.P: 282-285 曟, Yield 76%, IR (KBr, 
cm-1): 3 243 (N-H), 3 153(ArC-H), 2 938 (AliC-H), 1 663 (C=O, 
amide), 1 568 (C=C), 1 187 (O-C), 1H-NMR (DMSO-d6)毮: 
2.07 (s, 3H, CH3), 5.38 (s, 1H, CH), 6.69 (d, 2H, ArH), 7.53-7.68 
(m, 4H, ArH), 8.82 (s, 1H, NH), 9.51 (s, 1H, NH), 9.87 (s, 1H, 
NH). MS (m/z): M+ calculated 385.09, found 384.88.
2.3.11. 4-(2-chlorophenyl)-6-methyl-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4j)
   Ash-colored solid, M.P: 289-291 曟, Yield 72%, IR (KBr, 
cm-1): 3 247 (N-H), 3 148(ArC-H), 2 928 (AliC-H), 1 658 
(C=O, amide), 1 568 (C=C), 1 834 (C=S), 1 157 (O-C), 1H-NMR 
(DMSO-d6)毮: 2.06 (s, 3H, CH3), 5.63 (s, 1H, CH), 6.59 (d, 2H, 
ArH), 7.42-7.67 (m, 4H, ArH), 8.76 (s, 1H, NH), 9.39 (s, 1H, 
NH), 9.95 (s, 1H, NH). MS (m/z): M+ calculated 401.07, found 
401.76.
2.3.12. 4-(4-chlorophenyl)-6-methyl-2-oxo-N’-
(pyridin-4-ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4k)
   Light-bluish colored solid, M.P: 294-296 曟, Yield 79%, IR 
(KBr, cm-1): 3 258 (N-H), 3 152(ArC-H), 2 934 (AliC-H), 1 686 
(C=O, amide), 1 568 (C=C), 1 149 (O-C), 1H-NMR (DMSO-d6)
毮: 2.03 (s, 3H, CH3), 5.39 (s, 1H, CH), 6.72 (d, 2H, ArH), 7.46-
7.72 (m, 4H, ArH), 8.88 (s, 1H, NH), 9.38 (s, 1H, NH), 9.74 (s, 
1H, NH). MS (m/z): M+ calculated 385.09, found 385.84.
2.3.13. 4-(4-chlorophenyl)-6-methyl-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4l)
  Light-yellowish solid, M.P: 312-315 曟, Yield 73%, IR 
(KBr, cm-1): 3 256 (N-H), 3 174(ArC-H), 2 966 (AliC-H), 1 672 
(C=O, amide), 1 574 (C=C), 1 858 (C=S),1 134 (O-C), 1H-NMR 
(DMSO-d6)毮: 2.06 (s, 3H, CH3), 5.72 (s, 1H, CH), 6.49 (d, 2H, 
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ArH), 7.38-7.64 (m, 4H, ArH), 8.72 (s, 1H, NH), 9.68 (s, 1H, 
NH), 9.96 (s, 1H, NH). MS (m/z): M+ calculated 401.07, found 
400.92.
2.3.14. 4-(4-fluorophenyl)-6-methyl-2-oxo-N’-
(pyridin-4-ylcarbonyl)-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4m)
   Light-greenish solid, M.P: 328-331 曟, Yield 82%, IR (KBr, 
cm-1): 3 246 (N-H), 3 178(ArC-H), 2 936 (AliC-H), 1 646 (C=O, 
amide), 1 571 (C=C), 1 154 (O-C), 1H-NMR (DMSO-d6)毮: 
2.08 (s, 3H, CH3), 5.58 (s, 1H, CH), 6.44 (d, 2H, ArH), 7.36-7.69 
(m, 4H, ArH), 8.84 (s, 1H, NH), 9.58 (s, 1H, NH), 9.98 (s, 1H, 
NH). MS (m/z): M+ calculated 369.12, found 369.26
2.3.15. 4-(4-fluorophenyl)-6-methyl-N’-(pyridin-4-
ylcarbonyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carbohydrazide (4n)
   Light-bluish colored solid, M.P: 344-346 曟, Yield 78%, IR 
(KBr, cm-1): 3 246 (N-H), 3 134(ArC-H), 2 972 (AliC-H), 1 646 
(C=O, amide), 1 578 (C=C), 1 826 (C=S), 1 184 (O-C), 1H-NMR 
(DMSO-d6)毮: 2.09 (s, 3H, CH3), 5.74 (s, 1H, CH), 6.68 (d, 2H, 
ArH), 7.34-7.66 (m, 4H, ArH), 8.82 (s, 1H, NH), 9.56 (s, 1H, 
NH), 9.96 (s, 1H, NH). MS (m/z): M+ calculated 385.10, found 
385.84.
2.4. Antimicrobial activity
   The in vitro antibacterial activities were tested against 
Gram-positive bacteria Bacillus subtilis (B. subtilis) and 
Gram-negative bacteria Escherichia coli (E. coli) by 
standard serial dilution method using a stock solution of 100 
毺g/mL concentration[25,26].  Double strength nutrient broth 
was used as culture media and dimethyl sulphoxide (DMSO) 
was used as solvent control. The stock solutions of the test 
compounds were serially diluted in test tubes containing 
1 mL of sterile medium to get the different concentrations 
and then inoculated with 100 毺L of suspension of respective 
microorganism in sterile saline. Norfloxacin was used as 
standard drug. The inoculated test tubes were incubated at 
(37 依 1) 曟 for 24 h.
2.5. Antimycobacterial activity
   Antimycobacterial activity was performed following a 
protocol previously reported[27]. Compounds (4a - n) were 
preliminarily assayed against to freshly isolate clinical 
strains, M. furtuitum and M. tuberculosis, according to 
the dilution method in agar. Growth media were Mueller-
Hilton (Difco) containing 10% of OADC (oleic acid, albumin 
and dextrose complex) for M. furtuitum and Middle brook 
7H11 agar (Difco) with 10% of OADC for M. tuberculosis. 
Substances were tested at single dose of 100 毺g/mL. The 
compounds were then assayed for inhibitory activity against 
a panel of mycobacterial (M. tuberculosis CIP, M. tuberculosis 
H37Rv) in Middle brook 7H11 agar by a standard twofold 
dilution method. Plates were incubated at 37 曟 for 3 or 
28 d. Rifampicin was used as reference compound. After 
cultivation, MICs were read as minimal concentrations of 
drugs completely inhibiting visible of mycobacterial growth 
(Table 1).
3. Results
   A series of 14 novel isoniazid cyclocondensed 1,2,3,4-
tetrahydropyrimidines of biological interest were synthesized 
and evaluated for antimicrobial and anti-mycobacterial 
activity, all the compounds were characterized by IR, 1H 
NMR, MS for their structures.
3.1. Chemistry
   Synthesis of 1,2,3,4-tetrahydropyrimidines by microwave 
irradiation method reaction was performed by following steps 
as outlined in Figure 1. In the first step, ethylacetoacetate 2 
and isoniazid 1 reacted under neat conditions resulting in the 
formation of N’-acetoacetylisonicotinohydrazide 3 with the 
yield of 68 percent. The N’-acetoacetylisonicotinohydrazide 
was further taken for the condensation reaction by reacting 
it with urea/thiourea and appropriate aldehyde in the 
presence of catalytic amount of benzenesulphonic acid. 
The reaction times were found to be 8 minutes. Totally, 
fourteen compounds 4a-n, various substituted 1,2,3,4-
tetrahydropyrimidines, were synthesized with the yield 
ranging from 70 to 82 percent. These conditions enable 
this method to be applicable for the synthesis of 1,2,3,4-
tetrahydropyrimidines based heterocyclic compounds. The 
1,2,3,4-tetrahydropyrimidines, (4a-n) were synthesized 
relatively easily by using laboratory made benzenesulphonic 
acid as an efficient catalyst compared with Lewis acid. 
The present protocol best describes the synthesis of 
1,2,3,4-tetrahydropyrimidines. All the reported 1,2,3,4-
tetrahydropyrimidines compounds were found to be novel 
and not reported elsewhere.
O
O
O
O
O
O
O R
CH3
NH2
a
b
O
NH
N H3C
N
N
N
H
+ X
X
H2N
NHNH
NHNHNH
1 2
3
RCHO
+
NH2
H3C
H3C
Figure 1.  Synthesis of compounds (4a – 4n). 
Reagents  and condi t ions :  (a )  Ref lux  6  h ;  (b )  C 2H 5OH, 
Benzenesulphonic acid, microwave irradiation (300 W) for 8 min.
O
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3.2. Antimicrobial and antimycobacterial activity
   The synthesized compounds were subjected to in 
vitro antimicrobial activity against Gram-positive 
bacteria B. subtilis, Gram-negative bacteria E. coli and 
antimycobacterial against M. tuberculosis CIP and H37RV 
strain. The motive is to check the antimicrobial and 
antimycobacterial activity for the synthesized compounds. 
Almost all the titled compounds exhibited weak, moderate, 
or high antimicrobial and antimycobacterial activity.
   Analyzing the activities of the synthesized compounds, 
the following structure activity relationships (SARs) were 
obtained. The fifth position of 1,2,3,4-tetrahydropyrimidines 
contain N’-acetoacetylisonicotinohydrazide group 
contributed toward antimicrobial and  antimycobacterial 
and forth positions of 1,2,3,4-tetrahydropyrimidines contain 
substituted phenyl and hetero aromatic ring responsible 
antimicrobial and antimycobacterial potency. Substituted 
atom or group of atom must be strong electron withdrawing 
nature for potent activity because it decreases electron 
density in the ring due to inductive effect. Fluoride and 
chloride substitution at fourth position of phenyl ring 
showed potent antimicrobial and antimycobacterial action 
because of strong electron withdrawing nature. Substitution 
of chloro group at third position of phenyl ring showed 
potent action when compare with nitro atom. Among all the 
substituted phenyl ring, the activity order was F>Cl>NO2. 
Introduction of heterocyclic ring at forth position it showed 
moderate antimicrobial and antimycobacterial activity. 
Among the compounds reported here in, compound (4l, 4m, 
4n) is arguably the most potent when compare with current 
therapeutic agent norfloxacin and rifampicin because 
fluride and chloride substituted phenyl ring present at 4th 
position of 1,2,3,4-tetrahydropyrimidines it enhance the 
antimicrobial and antimycobacterial activity (Table 1).
4. Discussion
   A series of novel 1,2,3,4-tetrahydropyrimidines of 
biological interest were synthesized and analyzed for their 
structures. The libraries of compounds were prepared by 
using laboratory made benzenesulphonic acid as an efficient 
catalyst. The importance of substitutions at the fourth and 
fifth positions of 1,2,3,4-tetrahydropyrimidines was studied 
toward the antimicrobial and anti mycobacterial activity. The 
antimicrobial and anti mycobacterial activity data revealed 
that the all synthesized compounds proved to be active 
against the test organism B. subtilis, E. coli, M. tuberculosis 
CIP and H37RV strain. Almost all of the titled compounds 
exhibited weak, moderate, or high antimicrobial and 
antimycobacterial activity. Some of new derivatives showed 
an in vitro antimicrobial activity against B. subtilis, E. coli 
better than that of norfloxacin and antimycobacterial activity 
against M. tuberculosis CIP and H37RV strain better than that 
of antitubercular drug rifampicin. Among the compounds 
reported here in, compound (4l, 4m, 4n) is arguably the most 
potent, our present study makes it an interesting compound 
when compared to the current therapeutic agents and are 
considered the candidates to investigate further for the 
same.
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Table 1
Synthesized 1,2,3,4-tetrahydropyrimidines: Antimicrobial and antimycobacterial activity. 
S.No Compound R X
B. subtilis MIC 
(毺mol/mL)
E. coli MIC
 (毺mol/mL)
M. tuberculosis CIP MIC 
(毺g/mL)
M. tuberculosis H37Rv MIC
(毺g/mL)
1 4a 4-pyridyl O 0.012 9 0.013 0 1.41 1.47
2 4b 4-pyridyl S 0.012 6 0.012 8 1.24 1.21
3 4c 3-nitrophenyl O 0.014 1 0.014 3 2.73 2.97
4 4d 3-nitrophenyl S 0.137 0 0.013 9 2.62 2.66
5 4e 3-chlorophenyl O 0.013 9 0.014 0 2.34 2.36
6 4f 3-chlorophenyl S 0.013 5 0.013 8 2.13 2.18
7 4g 2-furyl O 0.015 7 0.016 3 5.28 5.35
8 4h 2-furyl S 0.015 3 0.015 8 4.62 4.87
9 4i 2-chlorophenyl O 0.013 7 0.014 1 2.04 2.07
10 4j 2-chlorophenyl S 0.013 4 0.013 9 1.92 1.96
11 4k 4-chlorophenyl O 0.011 6 0.012 3 1.07 1.09
12 4l 4-chlorophenyl S 0.011 1 0.012 0 1.40 1.06
13 4m 4-flurophenyl O 0.011 8 0.012 1 1.03 1.07
14 4n 4-flurophenyl S 0.011 2 0.011 9 1.01 1.04
15 Norfloxacin Standard - 0.012 4 0.023 7 - -
16 Rifampicin Standard - - - 1.06 1.08
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